Published Technical Disclosure Archive

Enhanced Bacillus Calmette-Guerin (BCG) and Antigen Presenting Cells for Bladder Cancer Treatment

Publication ID: 24-11857612_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Bacillus Calmette-Guerin (BCG) and Antigen Presenting Cells for Bladder Cancer Treatment,” Published Technical Disclosure No. 24-11857612_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857612_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,612.

Summary of the Inventive Concept

An improved vaccine composition and system for treating bladder cancer, enhancing immune response through the combination of immunotherapeutic primed antigen presenting cells, IL-15:IL-15Rα fusion protein complex, and bladder cancer-specific tumor antigen.

Background and Problem Solved

The original patent disclosed a vaccine composition for treating bladder cancer using antigen presenting cells and IL-15:IL-15Rα fusion protein complex. However, it had limitations in terms of enhancing immune response. The new inventive concept addresses this limitation by incorporating a bladder cancer-specific tumor antigen, which significantly enhances the immune response to bladder cancer cells.

Detailed Description of the Inventive Concept

The enhanced vaccine composition and system comprise immunotherapeutic primed antigen presenting cells isolated from a urine sample or bladder mucosa of an immunotherapeutic treated subject, and an IL-15:IL-15Rα fusion protein complex. The system further includes a bladder cancer-specific tumor antigen, which amplifies the immune response to bladder cancer cells. Additionally, the composition may include a checkpoint inhibitor to further enhance the immune response. The nanoparticle-based delivery system is also an optional component, providing targeted and controlled release of the vaccine composition.

Novelty and Inventive Step

The new claims introduce the combination of immunotherapeutic primed antigen presenting cells, IL-15:IL-15Rα fusion protein complex, and bladder cancer-specific tumor antigen, which is a novel and non-obvious improvement over the original patent. This combination provides a synergistic effect in enhancing immune response to bladder cancer cells.

Alternative Embodiments and Variations

Alternative embodiments may include varying the type of bladder cancer-specific tumor antigen, using different IL-15:IL-15Rα fusion protein complexes, or incorporating additional immunomodulatory molecules. The nanoparticle-based delivery system could be replaced with other targeted delivery systems, such as liposomes or viral vectors.

Potential Commercial Applications and Market

The enhanced vaccine composition and system have significant commercial potential in the treatment of bladder cancer, particularly in the non-muscle invasive bladder cancer market. The target industries include pharmaceutical companies, biotechnology companies, and research institutions focused on cancer immunotherapy.

CPC Classifications

SectionClassGroup
A A61 A61K39/04
A A61 A61K35/15
A A61 A61K39/00114
A A61 A61K39/001119
A A61 A61K39/39
A A61 A61K2039/515
A A61 A61K2039/585

Field of Art

Immunotherapy and cancer treatment, specifically bladder cancer immunotherapeutic approaches, requiring advanced knowledge in immunology, cell biology, and oncological therapeutic development

Person of Ordinary Skill (PHOSITA) Profile

A researcher with a PhD in immunology or cancer biology, experienced in developing immunotherapeutic strategies, familiar with antigen presenting cell manipulation, cytokine complexes, and cancer treatment methodologies

Obviousness Rationale

A PHOSITA would recognize that enhancing the source patent's BCG-based vaccine composition by incorporating additional tumor-specific antigens and checkpoint inhibitors represents a predictable extension of existing immunotherapeutic strategies. The combination of known immunological components to improve cancer treatment is a standard approach in the field. The PTD's modifications follow established scientific principles of augmenting immune responses through targeted molecular interventions.

Obvious Combinations & Variations

Source Patent Element
Antigen presenting cells isolated from BCG-treated subjects
PTD Variation
Adding bladder cancer-specific tumor antigen to enhance immune targeting
Obviousness Reasoning
Incorporating tumor-specific antigens is a known technique for improving immune recognition, representing a predictable optimization of existing immunotherapeutic approaches
Source Patent Element
IL-15:IL-15Rα fusion protein complex
PTD Variation
Combining fusion protein complex with checkpoint inhibitor
Obviousness Reasoning
Combining immunomodulatory molecules is a standard method for enhancing therapeutic efficacy, following established immunological combination strategies
Source Patent Element
Vaccine composition for bladder cancer treatment
PTD Variation
Introducing nanoparticle-based delivery system
Obviousness Reasoning
Targeted drug delivery systems are well-known in the art, representing a finite set of predictable technological solutions for improving therapeutic agent distribution
Source Patent Element
BCG-based immunotherapeutic approach
PTD Variation
Expanding composition to include multiple immunomodulatory components
Obviousness Reasoning
Systematic enhancement of immunotherapeutic compositions through multi-component approaches is a recognized method of improving treatment efficacy
Source Patent Element
Antigen presenting cell isolation from immunotherapeutic subjects
PTD Variation
Specifying isolation from urine sample or bladder mucosa
Obviousness Reasoning
Precise specification of biological sample sources is a routine optimization technique in biomedical research, representing a design choice within ordinary skill
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this Published Technical Disclosure would have been obvious to a Person Having Ordinary Skill In The Art at the time of invention, when viewed in light of US Patent 11857612. The systematic combination of known immunotherapeutic components, including tumor-specific antigens, checkpoint inhibitors, and targeted delivery systems, represents a predictable extension of existing bladder cancer treatment methodologies, thereby rendering potential patent claims obvious and unpatentable.

Original Patent Information

Patent NumberUS 11,857,612
TitleBacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Assignee(s)NantCell, Inc.